NCT02013180 · ADVERSE EVENTS

Adverse events

Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection · Source last updated 2019-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 4 years
Other-event reporting threshold: 0%

Not diiferent from the clinicaltrials.gov Definitions

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Prostate Cancer prostate adenocarcinoma in pathologic evaluation	0 / 119	0 / 119	0 / 119
Control benign prostatic diseases in pathologic evaluation	0 / 361	0 / 361	0 / 361

Group identifiers: EG000: Prostate Cancer · EG001: Control

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

description

Not diiferent from the clinicaltrials.gov Definitions

event Groups

deaths Num Affected
0
deaths Num At Risk
119
description
prostate adenocarcinoma in pathologic evaluation
id
EG000
other Num Affected
0
other Num At Risk
119
serious Num Affected
0
serious Num At Risk
119
title
Prostate Cancer
deaths Num Affected
0
deaths Num At Risk
361
description
benign prostatic diseases in pathologic evaluation
id
EG001
other Num Affected
0
other Num At Risk
361
serious Num Affected
0
serious Num At Risk
361
title
Control

frequency Threshold

time Frame

4 years

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice